Compare FGBI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | KZIA |
|---|---|---|
| Founded | 1934 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.1M | 154.5M |
| IPO Year | 2014 | 2002 |
| Metric | FGBI | KZIA |
|---|---|---|
| Price | $8.68 | $13.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 14.5K | ★ 182.5K |
| Earning Date | 04-27-2026 | 06-04-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $567.70 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.31 | $4.86 |
| 52 Week High | $11.02 | $17.40 |
| Indicator | FGBI | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 34.79 | 56.49 |
| Support Level | $7.83 | $11.39 |
| Resistance Level | $9.24 | $17.40 |
| Average True Range (ATR) | 0.33 | 1.08 |
| MACD | -0.04 | 0.23 |
| Stochastic Oscillator | 13.08 | 51.92 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana through several banking facilities. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and, to a lesser extent, consumer and multifamily loans. The company is engaged in a single line of business as a financial institution, which provides a full range of banking, financial, and trust services to state, county, and local government entities, individuals, and small and commercial businesses.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.